Citigroup
KYNB

Citigroup’s Kyntra Bio KYNB Stock Holding History

Citigroup’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$7 – 5900
2026
Q1 		$7 Buy
+1
New +$8 ﹤0.01% 5756
2025
Q4 		– Sell
-2,168
Closed -$26.6K – 6180
2025
Q3 		$26.6K Buy
+2,168
New +$20.4K ﹤0.01% 4718
2025
Q1 		– Sell
-1,531
Closed -$20.3K – 5700
2024
Q4 		$20.3K Buy
1,531
+1,527
+38,175% +$14.2K ﹤0.01% 5266
2024
Q3 		$42 Sell
4
-515
-99% -$7.77K ﹤0.01% 5570
2024
Q2 		$11.6K Sell
519
-185
-26% -$5.72K ﹤0.01% 5112
2024
Q1 		$41.3K Sell
704
-3,118
-82% -$134K ﹤0.01% 4712
2023
Q4 		$84.7K Buy
3,822
+1,543
+68% +$23.3K ﹤0.01% 4268
2023
Q3 		$49.2K Sell
2,279
-8,332
-79% -$327K ﹤0.01% 4147
2023
Q2 		$716K Sell
10,611
-13,218
-55% -$5.47M ﹤0.01% 3095
2023
Q1 		$11.1M Buy
23,829
+5,563
+30% +$2.94M 0.01% 1110
2022
Q4 		$7.32M Sell
18,266
-2,993
-14% -$1.15M 0.01% 1288
2022
Q3 		$6.92M Buy
21,259
+1,948
+10% +$627K ﹤0.01% 1358
2022
Q2 		$5.1M Buy
19,311
+17,278
+850% +$4.41M ﹤0.01% 1531
2022
Q1 		$610K Sell
2,033
-7,010
-78% -$2.44M ﹤0.01% 3371
2021
Q4 		$3.19M Buy
9,043
+1,440
+19% +$448K ﹤0.01% 2214
2021
Q3 		$1.94M Buy
7,603
+929
+14% +$329K ﹤0.01% 2571
2021
Q2 		$4.44M Buy
6,674
+1,452
+28% +$837K ﹤0.01% 1998
2021
Q1 		$4.53M Buy
5,222
+3,338
+177% +$3.55M ﹤0.01% 1853
2020
Q4 		$1.75M Buy
1,884
+866
+85% +$910K ﹤0.01% 2991
2020
Q3 		$1.05M Sell
1,018
-1,802
-64% -$1.94M ﹤0.01% 3235
2020
Q2 		$2.86M Buy
2,820
+98
+4% +$91K ﹤0.01% 2403
2020
Q1 		$2.37M Buy
2,722
+968
+55% +$962K ﹤0.01% 2328
2019
Q4 		$1.88M Sell
1,754
-2,357
-57% -$2.41M ﹤0.01% 3050
2019
Q3 		$3.8M Sell
4,111
-963
-19% -$1.06M ﹤0.01% 2185
2019
Q2 		$5.73M Buy
5,074
+3,605
+245% +$3.95M ﹤0.01% 1860
2019
Q1 		$2M Sell
1,469
-5,391
-79% -$7.31M ﹤0.01% 2645
2018
Q4 		$7.94M Buy
6,860
+5,316
+344% +$5.98M 0.01% 1435
2018
Q3 		$2.35M Buy
1,544
+841
+120% +$1.3M ﹤0.01% 2589
2018
Q2 		$1.1M Sell
703
-958
-58% -$1.25M ﹤0.01% 3260
2018
Q1 		$1.92M Sell
1,661
-2,277
-58% -$3M ﹤0.01% 2631
2017
Q4 		$4.67M Buy
3,938
+1,945
+98% +$2.44M ﹤0.01% 1900
2017
Q3 		$2.68M Buy
1,993
+391
+24% +$412K ﹤0.01% 2357
2017
Q2 		$1.29M Buy
1,602
+435
+37% +$303K ﹤0.01% 3051
2017
Q1 		$719K Sell
1,167
-3,734
-76% -$2.27M ﹤0.01% 3551
2016
Q4 		$2.62M Buy
4,901
+3,836
+360% +$1.92M ﹤0.01% 2612
2016
Q3 		$551K Sell
1,065
-1,855
-64% -$874K ﹤0.01% 3812
2016
Q2 		$1.2M Buy
2,920
+1,027
+54% +$470K ﹤0.01% 2779
2016
Q1 		$1.01M Sell
1,893
-1,077
-36% -$537K ﹤0.01% 3331
2015
Q4 		$2.26M Buy
2,970
+398
+15% +$264K ﹤0.01% 2395
2015
Q3 		$1.41M Sell
2,572
-3,198
-55% -$1.94M ﹤0.01% 2759
2015
Q2 		$3.39M Buy
5,770
+3,442
+148% +$2M ﹤0.01% 2086
2015
Q1 		$1.83M Buy
2,328
+2,264
+3,538% +$1.76M ﹤0.01% 2554
2014
Q4 		$44K Buy
+64
New +$41.2K ﹤0.01% 5773

Other funds holding KYNB

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Citigroup's KYNB Position: Q2 2026 in Review

Citigroup sold out of Kyntra Bio (KYNB) in Q2 2026, closing a stake of 1 share — an estimated $7 sold.

Citigroup first reported a position in KYNB in Q4 2014 and held it in 43 quarters. The position peaked at $11.1M in Q1 2023. 27 funds tracked by Wall St. Rank hold KYNB as of Q2 2026.

  • Citigroup reported no remaining Kyntra Bio position as of Q2 2026 after selling out during the quarter.
  • Citigroup sold 1 Kyntra Bio share in Q2 2026, an estimated $7.
  • Citigroup first reported a position in Kyntra Bio in Q4 2014 and held it in 43 quarters.
  • Citigroup's Kyntra Bio position peaked at $11.1M in Q1 2023.
  • 27 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.